Cinclus Pharma (Q4 Review): Phase III advancing on time - Redeye

Redeye provides a research update following the Q4 report published by Cinclus earlier today. While OPEX came in slightly above our estimates, this was offset by stronger-than-expected interest income and working capital effects. Overall, the financials did not contain any major surprises as the company continues to bolster a strong cash position. Importantly, Cinclus provided an update on the pivotal phase III study, stating that recruitment is advancing according to the time plan.

Länk till analysen i sin helhet: https://www.redeye.se/research/1151907/cinclus-pharma-q4-review-phase-iii-advancing-on-time?utm_source=finwire&utm_medium=RSS